CoChat

A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder

Open access
Szobot, C.M., Rohde, L.A., Katz, B., Ruaro, P., Schaefer, T., Walcher, M., Bukstein, O., Pechansky, F. · 2008 · Brazilian Journal of Medical and Biological Research

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Abstract

Our objective was to evaluate the effectiveness of a long-acting formulation of methylphenidate (MPH-SODAS) on attention-deficit/hyperactivity disorder (ADHD) symptoms in an outpatient sample of adolescents with ADHD and substance use disorders (SUD). Secondary goals were to evaluate the tolerability and impact on drug use of MPH-SODAS. This was a 6-week, single-blind, placebo-controlled crossover study assessing efficacy of escalated doses of MPH-SODAS on ADHD symptoms in 16 adolescents with ADHD/SUD. Participants were randomly allocated to either group A (weeks 1-3 on MPH-SODAS, weeks 4-6 on placebo) or group B (reverse order). The primary outcome measures were the Swanson, Nolan and Pelham Scale, version IV (SNAP-IV) and the Clinical Global Impression Scale (CGI). We also evaluated the adverse effects of MPH-SODAS using the Barkley Side Effect Rating Scale and subject reports of drug use during the study. The sample consisted of marijuana (N = 16; 100%) and cocaine users (N = 7; 43.8%). Subjects had a significantly greater reduction in SNAP-IV and CGI scores (P < 0.001 for all analyses) during MPH-SODAS treatment compared to placebo. No significant effects for period or sequence were found in analyses with the SNAP-IV and CGI scales. There was no significant effect on drug use. MPH-SODAS was well tolerated but was associated with more severe appetite reduction than placebo (P < 0.001). MPH-SODAS was more effective than placebo in reducing ADHD symptoms in a non-abstinent outpatient sample of adolescents with comorbid SUD. Randomized clinical trials, with larger samples and SUD intervention, are recommended.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/s0100-879x2008005000011

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flowchart of study design and procedures. ADHD = attention deficit/hyperactivity disorder; SUD = substance use disorder; R = randomization; K-SADS-E = Schedule for Affective Disorders and Schizophrenia for School - Age Children, Epidemiological Version; MINI = Mini International Neuropsychiatry Interview; PI = principal investigator; CGAS = Clinical Global Assessment Scale; IQ = Intelligence quotient; SNAP-IV = Swanson, Nolan, and Pelham Scale, version IV; CGI = Clinical Global Impression Scale; SERS = Barkley Side Effect Rating Scale; MPH = methylphenidate SODAS; PLA = placebo.
Figure 1 Flowchart of study design and procedures. ADHD = attention deficit/hyperactivity disorder; SUD = substance use disorder; R = randomization; K-SADS-E = Schedule for Affective Disorders and Schizophrenia for School - Age Children, Epidemiological Version; MINI = Mini International Neuropsychiatry Interview; PI = principal investigator; CGAS = Clinical Global Assessment Scale; IQ = Intelligence quotient; SNAP-IV = Swanson, Nolan, and Pelham Scale, version IV; CGI = Clinical Global Impression Scale; SERS = Barkley Side Effect Rating Scale; MPH = methylphenidate SODAS; PLA = placebo.CC-BY · From the PDF
Figure 2 SNAP-IV and CGI-Severity scores during the protocol for MPH-SODAS and placebo groups in adolescents with ADHD and SUD (N = 16). SNAP-IV = Swanson, Nolan, and Pelham Scale, version IV; CGI = Clinical Global Impression Scale; ADHD = attention deficit/hyperactivity disorder; SUD = substance use disorder. Group A: methylphenidate SODAS (MPH-SODAS) during weeks 1, 2, 3, and placebo during weeks 4, 5, and 6. Group B: placebo during weeks 1, 2, 3, and MPH-SODAS during weeks 4, 5, and 6.
Figure 2 SNAP-IV and CGI-Severity scores during the protocol for MPH-SODAS and placebo groups in adolescents with ADHD and SUD (N = 16). SNAP-IV = Swanson, Nolan, and Pelham Scale, version IV; CGI = Clinical Global Impression Scale; ADHD = attention deficit/hyperactivity disorder; SUD = substance use disorder. Group A: methylphenidate SODAS (MPH-SODAS) during weeks 1, 2, 3, and placebo during weeks 4, 5, and 6. Group B: placebo during weeks 1, 2, 3, and MPH-SODAS during weeks 4, 5, and 6.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 2

  1. National Institute of Mental Health, 1985, CGI (Clinical Global Impression) scale, Psychopharmacol Bull, 21, 839
  2. Littell RC, 2000, Modelling covariance structure in the analysis of repeated measures data, Stat Med, 19, 1793, 10.1002/1097-0258(20000715)19:13<1793::AID-SIM482>3.0.CO;2-Q · doi:10.1002/1097-0258(20000715)19:13<1793::aid-sim482>3.0.co;2-q

Cited by

See all 51

Metadata

Authors
Szobot, C. M., Rohde, L. A., Katz, B., Ruaro, P., Schaefer, T., Walcher, M., Bukstein, O., & Pechansky, F.
Affiliations
  • Universidade Federal do Rio Grande do Sul (BR)
  • Universidade Luterana do Brasil (BR)
  • University of Pittsburgh (US)
  • Centro de Pesquisas em Álcool e Drogas
Venue
Brazilian Journal of Medical and Biological Research
Published
2008-02-20
Volume
41
Issue
3
Pages
250-257
ISSN
  • 0100-879X (ISSN-L)
  • 1414-431X
OpenAlex
W2097467510
Cited by
51
References
37
Citations by year
2026: 1 · 2025: 4 · 2023: 3 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 1 · 2015: 4 · 2014: 3 · 2013: 3 · 2012: 3
FWCI
3.27
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Brazilian Journal of Medical and Biological Research (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, cc-by)
  • Americanae (AECID Library) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lume (Universidade Federal do Rio Grande do Sul) (submittedVersion, other-oa)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
Funders
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (307780/2004-0)
  • Hospital de Clínicas de Porto Alegre
  • Shire
  • National Institute on Drug Abuse
  • National Institute of Allergy and Infectious Diseases
  • Cilag
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
methylphenidate, long-acting stimulants, attention deficit hyperactivity disorder, substance use disorders, adolescents, comorbidities, cannabis use, cocaine use, ADHD symptom reduction, appetite suppression, tolerability
MeSH terms
Adolescent, Adult, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Humans, Male, Methylphenidate, Single-Blind Method, Treatment Outcome, Cross-Over Studies, Substance-Related Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. https://app.cochat.ai/papers/10.1590/s0100-879x2008005000011
The paper
Szobot, C. M., Rohde, L. A., Katz, B., Ruaro, P., Schaefer, T., Walcher, M., Bukstein, O., & Pechansky, F. (2008). A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/s0100-879x2008005000011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.